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ABSTRACT
Objective: The objective of this research work is to develop a simple, rapid, cost-effective, accurate, precise, and robust stability-indicating reverse-
phase ultra-high performance liquid chromatography method for the quantitative estimation of telmisartan (TEL) and amlodipine (AMD) in combined 
tablet dosage form.
Methods: The method uses Poroshell 120EC-C18 column (4.6 mm × 50 mm, 2.7 µm) with an optimized mobile phase containing acetonitrile:50 mM 
ammonium acetate buffer in the ratio (45:55 v/v), pH adjusted to 4.5 with acetic acid. The flow rate was 0.5 ml/min, column temperature at 25°C 
and detection was monitored by a PDA detector at a wavelength of 245 nm. International Conference on Harmonization (ICH) recommended stress 
degradation studies were performed on TEL, AMD standard drugs, and tablet formulations; further stressed samples were analyzed by the proposed 
method.
Results: Major degradation of TEL and AMD was observed under acidic, alkali, hydrolytic and oxidation conditions. The described method was 
validated as per the ICH guideline and validation parameters such as system suitability, linearity, accuracy, precision, specificity, and robustness 
results were within acceptable limits.
Conclusion: The method was found to be suitable and accurate for quantitative estimation and stability study of title drugs in pharmaceutical 
preparations.
Keywords: Telmisartan, Amlodipine, Reverse-Phase ultra-high-performance liquid chromatography, Forced degradation, Method validation.
INTRODUCTION
Telmisartan (TEL), chemically described as 2-(4-{[4-methyl-6-(1-
methyl-1H-1, 3-benzoimidiazol-2-yl)-2-propyl-1H-1, 3-benzoimidazole-
1-yl] methyl} phenyl) benzoic acid, molecular formula C33H30N4O2 and 
molecular weight 514.62. Amlodipine (AMD) is chemically described 
as 3-O-ethyl5-O-methyl-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-
6-methyl-1,4-dihydropyridine-3,5-dicarboxylate, molecular formula 
C20H25ClN2O5 and molecular weight 408.88 [1-3] Figs. 1 and 2.
TEL is an angiotensin II receptor antagonist which helps to lower 
arterial hypertension by inhibiting the angiotensin-converting enzyme 
that converts angiotensin I into its active form angiotensin II causes 
vasoconstriction. AMD in contrast is a dihydropyridine-class calcium 
channel blocker. AMD acts by blocking transmembrane calcium influx 
through the calcium channel, resulting in the relaxation of the smooth 
muscle in the arterial wall, decreasing peripheral resistance and hence 
reducing blood pressure. Combining the angiotensin II receptor antagonist 
TEL with the calcium channel blocker AMD has the added benefit of 
reducing cardiovascular mortality and morbidity over other dual therapies 
while providing equivalent blood pressure control. Each antihypertensive 
drug has been combined with multiple other antihypertensive medications 
into a single pill, but this combination is unique, due to the complementary 
mechanisms of its components appear to enhance the effectiveness beyond 
that provided by each drug alone [4-8].
To establish inherent stability characteristics of a drug, International 
Conference on Harmonization (ICH) stability testing guideline Q1A 
(R2) [9] suggests that stress studies should be carried out, leading to the 
identification of likely degradation products. For stability samples, it also 
requires that analytical test procedures should be stability indicating 
and they should be fully validated. The literature survey revealed that 
several analytical methods have been reported for the quantitative 
estimation of TEL alone and in combination with other drugs. Several 
reverse-phase high-performance liquid chromatography (RP-HPLC), 
high-performance thin-layer chromatography methods [10-19], 
ultraviolet (UV) spectroscopy method [20-23] were reported for 
estimation of TEL and AMD, but very few research papers have reported 
their degradation profile [24-27]. However, in the reported methods we 
found some drawbacks which are listed below.
• In one research paper forced degradation studies mentioned in the 
title, but in the entire research paper, no forced degradation methods 
and chromatograms were mentioned
• The buffer solution pH was adjusted to 3.6 mentioned in the research 
paper. The strong acidic condition may cause larger retention time 
(RT) for TEL as it remained fully undissociated, which results in 
strong hydrophobic attraction with silica bed.
Hence, it is thought of interest to develop new sensitive and accurate 
stability indicating reverse-phase ultra high-performance liquid 
chromatography (RP UHPLC) methods for effective quantitative 
estimation of TEL and AMD in the bulk and tablet dosage form. First pKa 
values of both drugs were investigated and pKa of TEL and AMD was 
found to be 4.45 and 9.45, respectively. As per thumb rule, the mobile 
phase pH is selected 2 units above or below the pKa value of the drug. 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i6.32629
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If we consider pKa of AMD, then we cannot choose the pH above 9.45, 
which cause hydrolysis of silica column bed. Therefore, the choice of pH 
is two units below the pKa of AMD. Again, with respect to TEL, we could 
choose the pH of mobile phase two units below of its pKa (4.45), but at 
strong acidic pH, TEL remains fully unionized, which results in strong 
hydrophobic attraction with silica bed that causes a longer RT of this 
drug. Therefore, we tried with a buffer like a phosphate buffer having the 
pH of around 7.0 with acetonitrile, which will be about two units far from 
the pKa of both drugs, and at this pH, both drugs will remain ionized, 
which makes the RT much shorter in short column length. Thus, we 
tried with different buffers having a pH between 4.5 and 6 with different 
ratios of acetonitrile in isocratic condition, and finally, ammonium acetate 
buffer pH of 4.5 with acetonitrile in the ratio (55:45 v/v) was chosen so as 
to get sufficient resolution between the peaks.
MATERIALS AND METHODS
Chemicals and reagents
TEL and AMD standard drugs were obtained as a gift sample from Micro 
Laboratories Limited, Hosur, India. The solvent methanol, acetonitrile, 
water and chemicals triethylamine, acetic acid and orthophosphoric 
acid used were of HPLC grade (Spectrochem, India). Sodium dihydrogen 
orthophosphate dehydrates, ammonium acetate (Merck India) sodium 
hydroxide, hydrochloric acid, hydrogen peroxide, used to be of AR 
grade (Fisher Scientific, India). The solvents and buffers for UHPLC 
used were filtered through Millipore nylon membrane filter (0.45 µm) 
and sonicated before use. The sample solutions for UHPLC were filtered 
through a 0.45 μm syringe filter before injections.
Instrumentation
Agilent 1260 UHPLC System consists of 1260 quaternary pump, 
standard autosampler, Poroshell 120EC-C18 column (4.6 × 50 mm, 
2.7 µm), PDA detector with Chemstation Software, ShimadzuAUX220 
Weighing Balance, Elico India LI 127 pH meter and Grant Sub-aqua 12 
Water bath, Shimadzu UV 1800 spectrophotometer, and ultrasonicator 
were used in the analysis.
Preparation of standard stock solutions
Preparation of diluents
Diluents used for the standards and sample solution preparations were 
as follows:
• Diluent A composed of methanol and acetonitrile in the ratio of 50:50 
(v/v).
• Diluent B composed of acetonitrile and water in the ratio of 40:60 
(v/v)
• Standard stock solutions were prepared by dissolving the drug in 
diluent A
Preparation of stock solution of telmisartan
An accurately weighed quantity of 25 mg of standard TEL was 
transferred into a 25 ml volumetric flask. Dissolved and diluted to 25 ml 
with diluents A to obtain the concentration of 1000 µg/ml.
Preparation of stock solution of amlodipine
An accurately weighed quantity of 25 mg of standard AMD was 
transferred into a 25 ml volumetric flask. Dissolved and diluted to 25 ml 
with diluent A to obtain the concentration of 1000 µg/ml.
Preparation of mixed standard solution
A binary mixture standard solution was prepared by pipetting out 4 ml 
of TEL and 0.5 ml of AMD from stock solution (1000 µg/ml), transferred 
into a 10 ml volumetric flask and the volume was made up to 10 ml using 
diluent B. This solution contained 400 µg/ml of TEL and 50 µg/ml of AMD.
Preparation of calibration curve standard solutions
A series of five different concentrations of calibration curve binary 
mixture standard solutions of TEL and AMD were prepared from the 
stock solution which is in the range from 380 to 420 µg/ml for TEL and 
30 to 70 µg/ml for AMD.
Preparation of sample solution
Twenty tablets of the commercial sample (Newtel AM, 40 mg and 5 mg) 
were weighed accurately and crushed to a fine powder. The tablet, 
powder equivalent 40 mg of TEL and 5 mg of AMD was weighed and 
transferred into a 100 volumetric flask. To this flask, 50 ml of diluents 
A was added, and the solution was sonicated for 30 min. The solution 
was cooled to ambient temperature. Then, the volume was made 
up to 100 ml with diluents B, filtered through Whatman filter paper 
and further filtered through 0.45 μm membrane filter. The prepared 
solution contains 400 µg/ml of TEL and 50 µg/ml of AMD.
Determination of detection wavelength
For the development of the method, UV spectrum of TEL and AMD was 
obtained separately by scanning the analytes at concentration levels 
Fig. 1: Structure of telmisartan
Fig. 2: Structure of amlodipine
Fig. 3: Ultraviolet spectrum of telmisartan and amlodipine
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of 10 µg/ml in the range from 400 nm to 200 nm against blank as 
methanol. After a thorough examination of the spectra, the wavelength 
of 245 nm was selected as symmetric peaks were obtained at this 
wavelength which is shown in Fig. 3.
Chromatographic conditions
The chromatographic separation was performed on Poroshell 120EC-
C18 column (4.6 mm × 50, 2.7 µm). The mobile phase was composed of 
acetonitrile and buffer in the ratio of (45: 55 v/v). The buffer used in the 
mobile phase contains 50 mM ammonium acetate in Mill Q water and 
pH was adjusted to 4.5 with acetic acid, filtered under vacuum through 
a 0.45 µm nylon filter and degassed in an ultrasonic bath before use. The 
mobile phase was pumped from the solvent reservoir to the column at a 
flow rate of 0.5 ml/min and the column temperature was maintained at 
25°C. The injection volume was 10 µl and the elute was monitored at a 
wavelength of 245 nm using photodiode array detector.
Procedure for forced degradation studies of standard drugs
Forced degradation studies of standard drugs and tablet formulation 
were carried out under thermolytic, photolytic, acid, base, and neutral 
hydrolytic and oxidative stress conditions [28, 29].
Acid degradation
Pipetting out 4 ml of TEL and 0.5 ml of AMD standard solutions from 
stock solutions (1000 µg/ml), transferred to a 10 ml volumetric flask, 
added 2 ml of 0.1N HCl and diluted up to 10 ml with diluent B. The 
solution was heated on a water bath at 60°C for 4 h. The solution was 
allowed to ambient temperature repeated the same with 1N HCl.
Alkali degradation
Pipetting out 4 ml of TEL and 0.5 ml of AMD standard solutions from 
stock solutions (1000 µg/ml), transferred to a 10 ml volumetric flask, 
added 2 ml of 0.1N NaOH, and diluted up to 10 ml with diluent B. The 
solution was heated on a water bath at 60°C for 4 h. The solution was 
allowed to ambient temperature repeated the same with 1N NaOH.
Degradation under the neutral hydrolytic condition
Pipetting out 4 ml of TEL and 0.5 ml of AMD standard solutions from 
stock solutions (1000 µg/ml), transferred to a 10 ml volumetric flask, 
added 2 ml of distilled water and diluted up to 10 ml with diluent B. The 
solution was heated on a water bath at 60°C for 8 h. The solution was 
allowed to ambient temperature.
Degradation under oxidative condition
Pipetting out 4 ml of TEL and 0.5 ml of AMD solutions from stock 
solutions (1000 µg/ml), transferred to a 10 ml volumetric flask, added 
2 ml of 3% v/v H2O2 and diluted up to 10 ml with diluent B. The solution 
was heated on a water bath at 60°C for 1 h.
Degradation under dry heat
Dry heat study was performed by keeping drug sample on a Petri dish 
(about 100 mg) in an oven at 80°C for 24 h. Cooled, samples were 
withdrawn, dissolved in diluent A to prepare a sample solution to get 
concentrations of 1000 µg/ml. Pipetting out 4 ml of TEL and 0.5 ml of 
AMD standard solution of the stock solution (1000 µg/ml), transferred 
to a 10 ml volumetric flask, and diluted up to 10 ml with diluent B.
Table 1: Results of forced degradation studies









Acidic 999.24 8.8 (0.1 N HCl) - 4.9 - 997.68
998.13 7.7 (1 N HCl) - 5.4 0.919 998.36
Alkali 998.68 2.7 (0.1 NaOH) - 1.1 - 997.87
996.87 2.9 (1 N NaOH) - 7.3 0.918 997.38
Hydrolytic 993.42 8.2 -- 72.8 - 999.77
Oxidative 997.46 21.9 4.193 11 1.027 999.62
Dry heat 999.45 0.4 - 0.6 - 999.96
UV light 999.72 100 - 100 - 999.39
Sun light 999.53 0.5 - 0.4 - 999.47
TEL: Telmisartan, AMD: Amlodipine, RT: Retention time, P: Peak purity, UV: Ultraviolet
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Fig. 5: (a) Ultra high-performance liquid chromatogram of 0.1N HCl degradation. (b) Ultra high-performance liquid chromatogram 
of 1N HCl degradation. (c) Ultra high-performance liquid chromatogram of 0.1N NaOH degradation. (d) Ultra high-performance 
liquid chromatogram of 1N NaOH degradation. (e) Ultra high-performance liquid chromatogram of neutral hydrolytic degradation. 
(f) Ultra high-performance liquid chromatogram of oxidative degradation. (g) Ultra high-performance liquid chromatogram of dry 
heat degradation. (h) Ultra high-performance liquid chromatogram of direct sunlight degradation. (i) Ultra high-performance liquid 
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Sunlight degradation studies
Sunlight study was performed by exposing the drug samples in a Petri 
dish (about 100 mg) directly to sunlight for 8 h for 7days. Samples were 
withdrawn, dissolved in diluent A to prepare sample solutions to get 
concentrations of 1000 µg/ml. Pipetting out 4 ml of TEL and 0.5 ml 
of AMD sample solutions and transferred the solution into a 10 ml 
volumetric flask and diluted up to 10 ml with diluent B.
Photo degradation studies
Photolytic studies were carried out by exposing the drugs in a Petri 
dish (about 100 mg) to UV short 254 nm and UV long light 366 nm 
for 24 h. Samples were withdrawn, dissolved in diluent A to prepare 
sample solutions to get concentrations of 1000 µg/ml. Pipetting out 
4 ml of TEL and 0.5 ml of AMD sample solutions and transferred the 
solution into a 10 ml volumetric flask and diluted up to 10 ml with 
diluent B.
Procedure for forced degradation studies of drug products
A forced degradation studies of the tablet formulation in acidic, 
basic, water hydrolysis, and oxidative conditions were carried out 
using filtered solution (as described in sample preparation) to 
achieve 400 µg/mlof TEL and 50 µg/ml of AMD. For thermolytic 
and photolytic degradation, a quantity of powder equivalent to one 
tablet containing 40 mg of TEL and 5 mg of AMD was exposed. Then, 
the solutions were prepared as described in the preparation of the 
sample solution.
RESULTS
Optimization of the chromatographic conditions
Chromatographic conditions were optimized with a view to developing 
a stability-indicating method for the simultaneous quantitative 
estimation of TEL and AMD. To achieve the objective, different 
chromatographic options such as the selection of the mobile phase 
and stationary phase were evaluated to obtain a better resolution, 
less run time, high sensitivity, and symmetric peak in the method 
development. To optimize mobile phase under the isocratic condition, 
initially different mobile phases containing mixtures of commonly 
used solvents, namely methanol, acetonitrile with or without different 
buffers such as ammonium acetate and phosphate with different 
volume were tested at a flow rate of 1.0 or 0.5 ml/min. Different ratios 
of acetonitrile and ammonium acetate buffer were tested at a flow rate 
of 1.0 or 0.5 ml/min. The final mobile phase containing a mixture of 50 
mM ammonium acetate in Mill Q water, pH adjusted to 4.5 with acetic 
acid and acetonitrile in the ratio of 55:45 was selected at a flow rate of 
0.5 ml/min. A nonpolar Poroshell 120EC-C18 column was chosen as the 
stationary phase for this study. The column was maintained at room 
temperature. The injection volume was 10 µl. A study baseline was 
recorded with optimized chromatographic conditions at a wavelength 
of 245 nm and stabilized for about 30 min. Adequate separation of 
both drugs with good peak shape and less tailing was obtained with 
these optimized chromatographic conditions which also separates 
the degradants from standard drugs. Under the above-optimized 
conditions, the RT of 1.768 and 3.831 min was obtained for AMD and 
TEL which is shown in Fig. 4a and b.




TEL AMD Acceptance criteria
Tailing factor 1.43 0.75 NMT 2.0%
Theoretical plate count 4892 4287 NLT 2000
The percentage RSD for 
the areas of five replicate 
injections of the peak
0.57 0.32 NMT 2.0%
RSD: Relative standard deviation, NMT: Not more than, TEL: Telmisartan,  
AMD: Amlodipine, NLT: Not less than




Table 3: Linearity study results of telmisartan and amlodipine
S. No TEL AMD
Concentration (µg/ml) Area response Concentration (µg/ml) Area response
1 380 21,987.07 30 1525.7
2 390 22,434.07 40 1983.7
3 400 22,816.13 50 2385.2
4 410 23,176.70 60 2795.6
5 420 23,605.71 70 3140.4
Slope 39.799 - 40.053
Intercept 6884.3 - 356.27
Regression coefficient 0.9987 - 0.9983
Correlation coefficient 0.9993 - 0.9991
LOD µg/ml 0.2927 - 0.1371
LOQ µg/ml 0.8893 - 0.1125
TEL: Telmisartan, AMD: Amlodipine, LOD: Limit of detection, LOQ: Limit of quantification
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Degradation observed
The chromatograms of the TEL and AMD standards and tablet 
formulation showed well-separated peaks of pure TEL and AMD as well 
as some additional degradants when they were subjected to various 
stress conditions such as acid, alkali, neutral, hydrogen peroxide, dry 
heat, sunlight, and UV light. The peaks of the degraded products were 
well resolved from the TEL and AMD drug’s peak. The identification of 
the degradants was carried out by comparing the chromatograms of 
“stressed samples” with that of the “standard solution.” In stress testing, 
the current regulatory guidelines do not provide sufficient information 
about degradation conditions. However, Blessy and Ruchi [30] in their 
article on stress testing suggested that a target degradation of 5–20% 
Fig. 7: Ultra high-performance liquid chromatograms of specificity study of telmisartan and amlodipine tablet (a and b) 0.1 and 1N N HCl 
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has been accepted as reasonable for validation of chromatography 
assay. Similarly, Singh and Bakshi [31] in their article on stress testing 
suggested a target degradation by 20–80% for establishing stability-
indicating studies and also intermediate degradation products should 
not interfere with any stage of drug analysis. In this study, conditions 
used for forced degradation were attenuated to achieve degradation in 
the range of 5%–80% for TEL and AMD drug substances. The numbers 
of degradation products with their RT and percentage degradation of 
TEL and AMD are listed in Table 1 and shown in Fig. 5a-i.
Method validation
The developed method has been validated according to the ICH 
guideline [32]. The validation parameters such as system suitability, 
linearity, precision/reproducibility, accuracy, specificity, and robustness 
were considered for the newly developed method.
System suitability
The system suitability of the method was tested by injecting one blank 
injection, five injections of TEL and AMD mixed standard solution of 
concentration 400 µg/ml, 50 µg/ml. System suitability parameters 
such as theoretical plates, tailing factor, and areas percentage relative 
standard deviation (R. S. D) were studied and found that all the system 
suitability parameters are within acceptance criteria. Results of system 
suitability studies are shown in Table 2.
Linearity
The linearity of the method was tested by preparing five different 
mixed standard solutions from 50% to 150% of TEL and AMD and 
injected in triplicate for each concentration. The mixed standard 
solutions contain the concentration ranges from 380 to 420 µg/ml for 
TEL and 30 to 70 µg/ml for AMD. From the chromatograms, linearity 
plots were drawn by taking concentrations on X-axis and area of peaks 
on Y-axis. The regression equations obtained for TEL and AMD were 
39.799x + 6884.4 and 40.053x + 356.27 which is shown in Fig. 6a 
and b. The linear regression coefficient and correlation coefficient 
values for TEL and AMD were found to be 0.9987, 0.9993, and 0.9983, 
0.9991 respectively, indicating a high degree of linearity which is 
shown in Table 3.
Precision (repeatability)
To demonstrate the system and method precision of the analytical 
method, a homogeneous standard solution of TEL and AMD having 
concentration 400 µg/ml and 50 µg/ml was analyzed for 6 times and 
RT and areas were measured and percentage R. S. D was calculated. 
Similarly, the intermediate precision of the method was determined 
by analyzing RT and areas of the mixed homogeneous standard 
solution having concentration 400 µg/ml and 50 µg/ml for 6 times 
on different days, by different analysts. The precision study results 
Table 4: Precision study results of telmisartan and amlodipine
Six injections TEL AMD
Area response RT (min) Area response RT (min)
Results of system precision
Mean±SD 22,844±98.3466 3.928±0.0090 2375.4±5.4543 1.786±0.0043
Percentage RSD 0.04 0.22 0.23 0.25
Results of method precision
Mean±SD 22,820.8±34.266 - 2370.5±9.4238 -
Percentage RSD 0.20 - 0.40 -
Results of intermediate precision
Mean±SD 22,738.9±21.2492 - 2316.3±7.7983 -.
Percentage RSD 0.13 - 0.34 -
SD: Standard deviation, RSD: Relative standard deviation, TEL: Telmisartan, AMD: Amlodipine, RT: Retention time
Table 6: Results of recovery study of amlodipine











50 5 25 29.3 97.6 0.1527 0.51 0.0881
50 5 25 29.6 98.5
50 5 25 29.4 98.1
100 5 45 48.9 97.7 0.1154 0.23 0.0666
100 5 45 49.1 98.3
100 5 45 49.1 98.2
150 5 65 68.7 98.1 0.3214 0.46 0.1855
150 5 65 69.3 99.0
150 5 65 68.8 98.2
SD: Standard deviation, RSD: Relative standard deviation, SEM: Standard error of mean
Table 5: Results of recovery study of telmisartan
Level of 
recovery (%)
Concentration taken  
(µg/ml)
Amount added  
(µg/ml)







50 40 340 376.8 99.2 0.1527 0.04 0.0881
50 40 340 376.6 99.1
50 40 340 376.9 99.2
100 40 360 399.4 99.8 0.100 0.03 0.0577
100 40 360 399.6 99.9
100 40 360 399.5 99.9
150 40 380 425.8 101.4 0.2645 0.06 0.1527
150 40 380 425.3 101.7
150 40 380 425.4 101.3
SD: Standard deviation, RSD: Relative standard deviation, SEM: Standard error of mean
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illustrate that the method is precise (R. S. D % <2) which is shown 
in Table 4.
Accuracy (recovery test)
The accuracy of the method was demonstrated by recovery studies. 
Recovery study was carried out in three different levels, with each 
level in triplicate for standard drugs (nine determinations). The known 
concentration of TEL and AMD standard drugs was spiked at 50%, 
100%, and 150% levels into the tablet sample solutions containing 
40 µg/ml of TEL and 5 µg/ml of AMD. The percentage recoveries were 
calculated by analyzing the prepared solutions which are shown in 
Tables 5 and 6. The average recovery of three levels (9 determinations) 
for TEL and AMD was 100% and 98.3%, respectively. The results of the 
accuracy study express that recovery is well within the limit. Hence, the 
developed method is accurate.
Specificity
Different forced degradation studies were carried out for specificity 
study. Tablet samples were stressed with different conditions (similar to 
standard drug degradation studies) and injected into the UHPLC system. 
Photodiode array detection was used as evidence of the specificity of 
the method and to evaluate the homogeneity of the drug peak. The peak 
purity values of TEL and AMD were 999.56 and 999.48, respectively, 
which are more than 997 for tablet samples at 245 nm which shows 
that the peaks of analyte were pure and also the formulation excipients 
and degradants were not interfering with the analyte peaks which are 
shown in Fig. 7a-i.
Robustness
The robustness of the method was evaluated after introducing small 
deliberate changes in experimental conditions in the analysis of TEL and 
AMD standard solution at the concentration of 400 µg/ml and 50 µg/ml 
and chromatograms were studied. In all conditions areas percentage R. S. 
D and tailing factors were within acceptance criteria. Hence, it is concluded 
that the analytical procedure is robust which are shown in Table 7.
Assay
The prepared sample solution of tablet formulation having a 
concentration of 400 µg/ml and 50 µg/ml for TEL and AMD was 
analyzed by the newly developed method. The standard and tablet 
sample solutions peak areas were compared to calculate the content of 
TEL and AMD which is shown in Table 8.
DISCUSSION
The peaks of the degradants were well resolved from the TEL and AMD 
drugʼs peak. The chromatogram of the acid degraded samples showed 
one additional peak of RT of 0.919 min for AMD. The chromatogram 
of the alkali degraded samples showed one additional peak of RT 
of 0.918 min for AMD. The chromatogram of the oxidation degraded 
samples showed one additional peak of RT of 1.027 min for AMD 
and one additional peak of RT of 4.193 min for TEL. No additional 
peaks were developed in water, dry heat, and UV light and sunlight 
degradation studies. Major degradation of TEL and AMD was observed 
under acidic, alkali, and hydrolytic and oxidation conditions. Very less 
degradation was observed under dry heat and photolytic conditions.
The response of the drugs was found to be linear in the concentration 
range of 380–420 µg/ml for TEL and 30–70 µg/ml for AMD, respectively, 
with respect to the peak areas. The percentage R. S. D values for 
precision studies were found to be <2%; this confirms that the method 
is precise. The accuracy of the method was determined and the mean 
recovery of TEL and AMD were 100.0% and 98.3%, respectively. The 
peak purity values for TEL and AMD were in the range of 997–1000 
for drug substance as well as tablet formulation, indicating the peaks 
were pure and also that formulation excipients and degradants were 
not interfering with analyte peaks, thus establishing the specificity of 
the method. The low values of percentage R. S. D were obtained after 
introducing small deliberate changes in the developed UHPLC method, 
shows that the method is robust.
CONCLUSIONS
The developed isocratic RP-UHPLC method is highly sensitive, 
specific, accurate, and rapid with less run time and less consumption 
of solvents. The statistical analysis proved that the proposed method 
is reproducible, selective for the analysis of TEL and AMD in bulk and 
tablet formulations without any interference from common excipients. 
The proposed method separates the drug from its degradants. The 
developed method can be employed to isolate degradants and for 
routine quality control analysis of TEL and AMD tablets.
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Table 7: Results of robustness for telmisartan and amlodipine
Parameters TEL AMD
Area percentage RSD Tailing factor Area percentage RSD Tailing factor
Change in column temperature in (±5°C)
20 0.5532 0.96 0.5162 0.84
25 (initial) 0.0679 1.11 0.2974 0.92
30 0.4235 1.02 0.1946 0.93
Change in mobile phase composition 
buffer: Acetonitrile (organic phase±2%)
57:43 0.1348 1.06 0.3642 0.96
55:45 (initial) 0.1035 0.86 0.9149 1.14
53:47 0.1168 1.19 0.4746 0.93
Change in flow rate±0.2 ml/min
0.48 0.1846 1.15 0.3842 0.97
0.5 (initial) 0.1261 1.24 0.9275 0.91
0.52 0.2666 1.03 0.4632 1.09
RSD: Relative standard deviation, TEL: Telmisartan, AMD: Amlodipine
Table 8: Assay results of telmisartan and amlodipine
Tablet formulation Label claimed (mg/tablet) Amount found (mg) (n=3) Drug content (%) SD RSD SEM
TEL 40 39.8867 99.71 0.6321 0.63 0.3649
AMD 5 5.0264 100.52 0.9764 0.97 0.5637
TEL: Telmisartan, AMD: Amlodipine, SD: Standard deviation, RSD: Relative standard deviation, SEM: Standard error of mean
258
Asian J Pharm Clin Res, Vol 12, Issue 6, 2019, 250-258
 Patra et al. 
AUTHORS’ CONTRIBUTIONS
Biswa Ranjan Patra has carried out a review of literature and 
experimental work in the department of pharmaceutical analysis 
laboratory, PES College of Pharmacy, Bengaluru. Dr. Nagaraj Gowda 
drafted the manuscript. The final draft of the manuscript was reviewed 
and edited under the guidance of Dr. Mohan S.
CONFLICTS OF INTEREST STATEMENT
The authors declare that there are no conflicts of interest regarding the 
publication of the research paper.
REFERENCES
1. The Indian Pharmacopoeia. The Indian Pharmacopoeia Commission. 
6th ed., Vol. 2 and 3, Ghaziabad: The Indian Pharmacopoeia; 2010. 
p. 806-7, 2186-7.
2. Available from: http://www.drugbank.com. [Last accessed on 2019 
Apr 30].
3. Beale JM Jr., Block JH. Wilson and Gisvold’s Textbook of Organic 
Medicinal and Pharmaceutical Chemistry. 12th ed. New Delhi: Wolters 
Kluwer (India) Pvt., Ltd.; 2011. p. 613-4, 623-6.
4. Billecke SS, Marcovitz PA. Long-term safety and efficacy of 
telmisartan/amlodipine single pill combination in the treatment of 
hypertension. Vasc Health Risk Manag 2013;9:95-104.
5. White WB, Littlejohn TW, Majul CR, Oigman W, Olvera R, Seeber M, 
et al. Effects of telmisartan and amlodipine in combination on 
ambulatory blood pressure in stages 1-2 hypertension. Blood Press 
Monit 2010;15:205-12.
6. Vadillo AC, González MA, Alegre EG, Rodríguez A, García JG. Effect 
of a combination of telmisartan and amlodipine in hypertensive dogs. 
Vet Rec Case Rep 2018;9:1-6.
7. Fogari R, Derosa G, Zoppi A, Preti P, Lazzari P, Destro M, et al. 
Effect of telmisartan-amlodipine combination at different doses on 
urinary albumin excretion in hypertensive diabetic patients with 
microalbuminuria. Am J Hypertens 2007;20:417-22.
8. Ohishi M, Kawai T, Hayashi N, Kitano S, Katsuya T, Nagano M, et al. 
Effect of tablets with a combination of telmisartan and amlodipine 
on patients with hypertension: The cotalo study. Hypertens Res 
2013;36:620-6.
9. International Conference on Harmonisation (ICH) Guidelines. Q1A 
(R2) for Stability Testing of New Drug Substances and Products. 
Geneva, Switzerland: International Conference on Harmonization; 
2003.
10. Pawar HA, Yadav A. Development and application of RP-HPLC 
method for dissolution study of oral formulations containing amlodipine 
besylate. Indian J Chem Technol 2016;23:210-5.
11. Sinha SK, Shrivastava PK, Shrivastava SK. Development and validation 
of a HPLC method for the simultaneous estimation of amlodipin and 
telmisartan in pharmaceutical dosage form. Asian Pac J Trop Biomed 
2012;2:S312-5.
12. Panchal JG, Patel RV, Mistry BR, Menon SK. Development and 
validation of reversed-phase LC method for simultaneous determination 
telmisartan, amlodipine and their degradation products in fixed dose 
combination tablets. Eurasian J Anal Chem 2012;7:28-42.
13. Rajitha S, Biswal VB, Reddy DN, Ramesh B. Method development 
and validation of telmisartan and amlodipine besylate by RP-HPLC in 
tablet dosage form. Int J Pharm Sci 2013;3:365-9.
14. Kumar GV, Rajendraprasad Y. Development and validation of reverse 
phase HPLC method for simultaneous estimation of telmisartan and 
amlodipine in tablet dosage form. Int J Pharm Pharm Sci 2010;2:128-31.
15. Madhukar A, Kannappan N, Kumar CB. Analytical method development 
and validation for the determination of hydrochlorothiazide, amlodipine 
besylate and telmisartan hydrochloride in multicomponent tablet 
dosage form and in biorelevant media (fassif) byRP-HPLC techniques. 
Int J Pharm Pharm Sci 2015;7:218-25.
16. Jain PS, Patel MK, Bari SB, Surana SJ. Development and validation 
of HPTLC method for simultaneous determination of amlodipine 
besylate and metoprolol succinate in bulk and tablets. Indian J Pharm 
Sci 2012;74:152-6.
17. Chabukswar AR, Jagdale SC, Kumbhar SV, Kadam VJ, Patil VD, 
Kuchekar BS, et al. Simultaneous HPTLC estimation of telmisartan 
and amlodipine besylate in tablet dosage form. Arch Appl Sci Res 
2010;2:94-100.
18. Vekariya NR, Patel MB, Patel GF, Dholakiya RB. Development and 
validation of TLC-densitometry method for simultaneous determination 
of telmisartan and amlodipine besylate in bulk and tablets. J Young 
Pharm 2009;1:259-63.
19. Wal P, Tiwari R, Wal A, Tiwari G. Versatile RP-HPLC method 
development for quantitative estimation of telmisartan and ramipril in 
animal plasma. Int J Appl Pharm 2018;10:51-8.
20. Kondawar MS, Kamble KG, Raut KS, Maharshi KH. UV 
spectrophotometric estimation of amlodipine besylate and telmisartan 
in bulk drug and dosage form by multi wavelength analysis. Int J 
ChemTech Res 2011;3:1274-8.
21. Thomas AB, Jagdale SN, Dighe SB, Nanda RK. Simultaneous 
spectrophotometric estimation of amlodipine besylate and telmisartan 
in tablet dosage form. Int J ChemTech Res 2010;2:1334-41.
22. Pawar PY, Raskar MA, Kalure SU, Kulkarni RB. Simultaneous 
spectrophotometric estimation of amlodipine besylate and telmisartan 
intablet dosage form. Pharm Chem 2012;4:725-30.
23. Shakya P, Jain PK, Gajbhiye A, Shrivastava SP. Simultaneous estimation 
of telmisartan and hydrochlorothiazide by derivative spectroscopy. Int J 
Pharm Pharm Sci 2015;7:386-8.
24. Santosh KM, Rao VJ. Development and validation of a stability 
indicating RP-HPLC method for simultaneous determination of 
telmisartan and amlodipine in combined dosageform. Asian J Pharm 
Clin Res 2014;7:32-5.
25. Shinde P, Patil PM. Stability indicating spectrophotometric method of 
amlodipine and telmisartan in bulk and pharmaceutical dosage form. Int 
J Pharm Sci Rev Res 2014;26:19-24.
26. Shitole S, Gurjar M, Shah M, Pimple S, Bal G, Patel R, et al. 
Development and validation of a stability indicating RP-HPLC method 
for simultaneous estimation of related substances of s(-)amlodipine and 
telmisartan in fixed dose combination tablet dosage form. Chromatogr 
Res Int 2014;2014:1-9.
27. Kranthi M, Srinivas A. Analytical method development and validation 
and force degradation studies for simultaneous estimation of amlodipine 
besylate and telmisartan in tabletdosage form by using RP-HPLC. Int J 
Pharm Phytopharmacol Res 2014;4:2-7.
28. Iram F, Iram H, Iqbal A, Husain A. Forced degradation studies. J Anal 
Pharm Res 2016;3:1-5.
29. Venkataraman S, Merugu M. Forced degradation studies: Regulatory 
guidance, characterization of drugs, and their degradation products-a 
review. Drug Invent Today 2018;10:137-46.
30. Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of forced 
degradation and stability indicating studies of drugs-a review. J Pharm 
Anal 2014;4:159-65.
31. Bakshi M, Singh S. Development of validated stability-indicating assay 
methods-critical review. J Pharm Biomed Anal 2002;28:1011-40.
32. ICH Harmonized Tripartite Guideline. Validation of Analytical 
Procedure: Text and Methodology Q2 (R1). Geneva: International 
Conference on Harmonization; 2005.
